皓元医药
(688131)
| 流通市值：155.66亿 | | | 总市值：155.66亿 |
| 流通股本：2.12亿 | | | 总股本：2.12亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,059,065,717.06 | 1,310,942,751.62 | 606,125,018.69 | 2,270,177,811.5 |
| 营业收入 | 2,059,065,717.06 | 1,310,942,751.62 | 606,125,018.69 | 2,270,177,811.5 |
| 二、营业总成本 | 1,692,413,729.4 | 1,083,752,794.05 | 500,107,881.66 | 1,900,882,004.66 |
| 营业成本 | 1,034,805,413.89 | 667,674,761.08 | 311,648,334.05 | 1,181,279,071.54 |
| 税金及附加 | 12,103,221.6 | 6,413,450.95 | 2,972,567.81 | 13,251,425.49 |
| 销售费用 | 205,882,863.8 | 130,223,926.22 | 55,123,962.3 | 209,908,171.73 |
| 管理费用 | 223,745,202.1 | 145,848,900.37 | 67,836,339.46 | 234,994,900.01 |
| 研发费用 | 177,277,912.36 | 116,902,479.74 | 53,713,674.32 | 226,932,038.19 |
| 财务费用 | 38,599,115.65 | 16,689,275.69 | 8,813,003.72 | 34,516,397.7 |
| 其中:利息费用 | 21,065,953.61 | 13,844,753.89 | 6,348,625.94 | 31,326,271.51 |
| 其中:利息收入 | 8,970,985.59 | 5,123,337.15 | 2,142,974 | 7,482,216.02 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 118,000 | 212,602.74 | - | 150,068.49 |
| 加:投资收益 | 540,544.94 | 1,247,313.04 | 1,329,224.95 | -13,757,656.87 |
| 资产处置收益 | 559,743.27 | 616,971.72 | 9,351.07 | -567,191.03 |
| 资产减值损失(新) | -89,566,352.17 | -60,966,824.59 | -29,845,261.8 | -131,359,593.72 |
| 信用减值损失(新) | -14,070,586.67 | -5,234,127.13 | -7,927,872.33 | -16,324,015.96 |
| 其他收益 | 25,151,281.02 | 21,658,012.47 | 5,310,017.89 | 29,379,959.17 |
| 四、营业利润 | 289,384,618.05 | 184,723,905.82 | 74,892,596.81 | 236,817,376.92 |
| 加:营业外收入 | 1,616,203.21 | 359,501.71 | 143,918.86 | 2,352,504.76 |
| 减:营业外支出 | 3,575,703.63 | 3,461,032.3 | 1,777,944.09 | 814,600.33 |
| 五、利润总额 | 287,425,117.63 | 181,622,375.23 | 73,258,571.58 | 238,355,281.35 |
| 减:所得税费用 | 55,746,261.77 | 32,926,087.92 | 12,080,277.92 | 40,425,246.77 |
| 六、净利润 | 231,678,855.86 | 148,696,287.31 | 61,178,293.66 | 197,930,034.58 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 231,678,855.86 | 148,696,287.31 | 61,178,293.66 | 197,930,034.58 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 236,658,760.91 | 151,761,472.63 | 62,384,400.02 | 201,590,085.66 |
| 少数股东损益 | -4,979,905.05 | -3,065,185.32 | -1,206,106.36 | -3,660,051.08 |
| 扣除非经常损益后的净利润 | 223,173,725.84 | 140,571,127.52 | 58,917,994.16 | 178,952,687.06 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.12 | 0.72 | 0.3 | 0.96 |
| (二)稀释每股收益 | 1.12 | 0.72 | 0.3 | 0.96 |
| 八、其他综合收益 | -1,723,831.95 | -2,272,927.51 | 200,385.54 | 22,673,517.39 |
| 归属于母公司股东的其他综合收益 | -1,723,831.95 | -2,272,927.51 | 200,385.54 | 22,673,517.39 |
| 九、综合收益总额 | 229,955,023.91 | 146,423,359.8 | 61,378,679.2 | 220,603,551.97 |
| 归属于母公司股东的综合收益总额 | 234,934,928.96 | 149,488,545.12 | 62,584,785.56 | 224,263,603.05 |
| 归属于少数股东的综合收益总额 | -4,979,905.05 | -3,065,185.32 | -1,206,106.36 | -3,660,051.08 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-30 | 2025-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |